Hypertension Research Unit, Department of Medical and Surgical Sciences, University of Bologna, 40126 Bologna, Italy.
Cardiology Department and Intensive Care Unit, Toranomon Hospital, Tokyo 40138, Japan.
Medicina (Kaunas). 2021 Jan 10;57(1):58. doi: 10.3390/medicina57010058.
This article aims to critically review the evidence on the available therapeutic strategies for the treatment of hyperuricemia. For this reason, several papers were reviewed. Xanthine oxidase inhibitors are the safest and most effective uric acid lowering drugs for the management of chronic hyperuricemia, while the efficacy of uricosuric agents is strongly modulated by pharmacogenetics. Emergent drugs (lesinurad, peglotidase) were found to be more effective for the acute management of refractory hyperuricemia, but their use is supported by a relatively small number of clinical trials so that further well-designed clinical research is needed to deepen their efficacy and safety profile.
本文旨在批判性地回顾现有治疗高尿酸血症的治疗策略的证据。为此，综述了几篇论文。黄嘌呤氧化酶抑制剂是治疗慢性高尿酸血症最安全、最有效的降尿酸药物，而尿酸排泄剂的疗效受药物遗传学的强烈调节。新型药物（lesinurad、peg lotidase）被发现对难治性高尿酸血症的急性治疗更有效，但由于它们的临床应用仅基于相对较少的临床试验，因此需要进一步进行精心设计的临床研究，以加深其疗效和安全性。
